NEUMORA THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
NEUMORA THERAPEUTICS, INC. (NMRA) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $7.18 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-14
- NEUMORA THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $7.18M, a 0.27% increase year-over-year.
- NEUMORA THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $7.41M, a 20.58% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $5.98M, a 39.88% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $7.17M, a 43.88% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $29.88M, a 25.29% decline from fiscal 2024.
- NEUMORA THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $39.99M, a 131.96% increase from fiscal 2023.
- NEUMORA THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $17.24M, a 107.76% increase from fiscal 2022.
- NEUMORA THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $8.30M.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.18M 10-Q · filed 2026-08-14 | $14.59M derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $7.41M 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $29.88M 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $5.98M 10-Q · filed 2025-11-06 | $13.14M derived: sum of 2 quarters · filed 2026-08-14 | $22.47M derived: sum of 3 quarters · filed 2026-08-14 | |
| 2025-06-30 | $7.17M 10-Q · filed 2026-08-14 | $16.49M derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $9.32M 10-Q · filed 2026-08-14 | |||
| 2024-12-31 | $39.99M 10-K · filed 2026-03-30 | |||
| 2024-09-30 | $9.95M 10-Q · filed 2025-11-06 | $22.71M derived: sum of 2 quarters · filed 2025-11-06 | $30.09M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $12.77M 10-Q · filed 2025-11-06 | $20.14M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $7.37M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $17.24M 10-K · filed 2025-03-03 | |||
| 2023-09-30 | $6.45M 10-Q · filed 2024-11-12 | $8.99M derived: sum of 2 quarters · filed 2024-11-12 | $11.19M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $2.54M 10-Q · filed 2024-11-12 | $4.74M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $2.19M 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $8.30M 10-K · filed 2025-03-03 | |||
| 2022-09-30 | $2.10M 10-Q · filed 2023-11-01 | $3.85M derived: sum of 2 quarters · filed 2023-11-01 | $5.51M derived: sum of 3 quarters · filed 2023-11-01 | |
| 2022-06-30 | $1.75M 10-Q · filed 2023-11-01 | $3.40M derived: sum of 2 quarters · filed 2023-11-01 | ||
| 2022-03-31 | $1.65M 10-Q · filed 2023-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |